NRXP (NRX Pharmaceuticals) Total Receivables : $0.01 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NRX Pharmaceuticals Total Receivables?

NRX Pharmaceuticals's Total Receivables for the quarter that ended in Sep. 2024 was $0.01 Mil.

NRX Pharmaceuticals Total Receivables Historical Data

The historical data trend for NRX Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Total Receivables Chart

NRX Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Receivables

0.83

0.01

NRX Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Receivables	Get a 7-Day Free Trial													0.01	0.01	0.01	0.01	0.01

NRX Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

NRX Pharmaceuticals Total Receivables Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Executives

Richard Clavano Narido	officer: Interim CFO	12 HANSEN CT, MORAGA CA 94556
Aaron Gorovitz	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Chaim Hurvitz	director	C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733
Jonathan C Javitt	director, 10 percent owner, officer: Chief Scientist	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Stephen H Willard	director, officer: Chief Executive Officer	1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801
Daniel C. Javitt	10 percent owner	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Patrick John Flynn	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Ira S Strassberg	officer: Chief Financial Officer	C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170
Robert Besthof	officer: Chief Comm. & Patient Officer	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Alessandra Daigneault	officer: General Counsel & Secretary	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Herbert Raymond Mcmaster	director	C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113
Sharon Glied	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Richard Ackerman	director, 10 percent owner, officer: President & CEO	2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483
Big Rock Partners Sponsor, Llc	10 percent owner	2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483